Diseases such as obesity, type 2 diabetes, and nonalcoholic steatohepatitis (now called metabolic dysfunction-associated steatohepatitis (20)) have been treated with FGF21 analogs, with promising results (19,21,22). This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.